|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Brigham and Women's Hospital Celgene Corporation Genentech |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00142168 |
The purpose of this study is to determine the number of patients with Waldenstrom's macroglobulinemia that will benefit from treatment with CC-5103 and rituximab, what the side effects are and how long the benefit will last.
Condition | Intervention | Phase |
Waldenstrom's Macroglobulinemia |
Drug: CC-5103 Drug: Rituximab |
Phase II |
Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Rituximab Lenalidomide CC 5013 CC 5103 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia |
Estimated Enrollment: | 25 |
Study Start Date: | September 2004 |
Estimated Study Completion Date: | May 2008 |
Primary Completion Date: | May 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Beth Israel Deaconess Medical Center | |||||
Boston, Massachusetts, United States, 02215 |
Dana-Farber Cancer Institute |
Beth Israel Deaconess Medical Center |
Brigham and Women's Hospital |
Celgene Corporation |
Genentech |
Principal Investigator: | Steven Treon, MD, MA, PhD | Dana-Farber Cancer Insitute |
Responsible Party: | Dana-Farber Cancer Institute ( Steven Treon, MD, MA, PhD ) |
Study ID Numbers: | 04-158 |
First Received: | September 1, 2005 |
Last Updated: | December 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00142168 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|